Informed consent in oncology clinical trials: A Brown University Oncology Research Group prospective cross-sectional pilot study

por Schumacher, Andrew, Sikov, William M., Quesenberry, Matthew I., Safran, Howard, Khurshid, Humera, Mitchell, Kristen M., Olszewski, Adam J.
Publicado 2017

Quantitative measurements of HER2 and phospho-HER2 expression: correlation with pathologic response to neoadjuvant chemotherapy and trastuzumab

por Cheng, Huan, Bai, Yalai, Sikov, William, Sinclair, Natalie, Bossuyt, Veerle, Abu-Khalaf, Maysa M, Harris, Lyndsay N, Rimm, David L
Publicado 2014

Identification of stromal ColXα1 and tumor-infiltrating lymphocytes as putative predictive markers of neoadjuvant therapy in estrogen receptor-positive/HER2-positive breast cancer

por Brodsky, Alexander S., Xiong, Jinjun, Yang, Dongfang, Schorl, Christoph, Fenton, Mary Anne, Graves, Theresa A., Sikov, William M., Resnick, Murray B., Wang, Yihong
Publicado 2016

Weekly vs Every-3-Week Carboplatin with Weekly Paclitaxel in Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Retrospective Analysis

por Landry, Kara K, Lyon, Jessica L, Victoria, Kitty E, Changizzadeh, P Nick, Cole, Bernard F, Pulluri, Bhargavi, Sikov, William M, Wood, Marie E
Publicado 2022

AKT/mTOR signaling modulates resistance to endocrine therapy and CDK4/6 inhibition in metastatic breast cancers

por Abu-Khalaf, Maysa M., Alex Hodge, K., Hatzis, Christos, Baldelli, Elisa, El Gazzah, Emna, Valdes, Frances, Sikov, William M., Mita, Monica M., Denduluri, Neelima, Murphy, Rita, Zelterman, Daniel, Liotta, Lance, Dunetz, Bryant, Dunetz, Rick, Petricoin, Emanuel F., Pierobon, Mariaelena
Publicado 2023

Association of Peritumoral Radiomics With Tumor Biology and Pathologic Response to Preoperative Targeted Therapy for HER2 (ERBB2)–Positive Breast Cancer

por Braman, Nathaniel, Prasanna, Prateek, Whitney, Jon, Singh, Salendra, Beig, Niha, Etesami, Maryam, Bates, David D. B., Gallagher, Katherine, Bloch, B. Nicolas, Vulchi, Manasa, Turk, Paulette, Bera, Kaustav, Abraham, Jame, Sikov, William M., Somlo, George, Harris, Lyndsay N., Gilmore, Hannah, Plecha, Donna, Varadan, Vinay, Madabhushi, Anant
Publicado 2019

Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness

por Metzger-Filho, Otto, Collier, Katharine, Asad, Sarah, Ansell, Peter J., Watson, Mark, Bae, Junu, Cherian, Mathew, O’Shaughnessy, Joyce, Untch, Michael, Rugo, Hope S., Huober, Jens B., Golshan, Mehra, Sikov, William M., von Minckwitz, Gunter, Rastogi, Priya, Li, Lang, Cheng, Lijun, Maag, David, Wolmark, Norman, Denkert, Carsten, Symmans, W. Fraser, Geyer, Charles E., Loibl, Sibylle, Stover, Daniel G.
Publicado 2021

Luminal androgen receptor breast cancer subtype and investigation of the microenvironment and neoadjuvant chemotherapy response

por Thompson, Kevin J, Leon-Ferre, Roberto A, Sinnwell, Jason P, Zahrieh, David M, Suman, Vera J, Metzger, Filho Otto, Asad, Sarah, Stover, Daniel G, Carey, Lisa, Sikov, William M, Ingle, James N, Liu, Minetta C, Carter, Jodi M, Klee, Eric W, Weinshilboum, Richard M, Boughey, Judy C, Wang, Liewei, Couch, Fergus J, Goetz, Matthew P, Kalari, Krishna R
Publicado 2022

CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Nega...

por Shepherd, Jonathan H., Ballman, Karla, Polley, Mei-Yin C., Campbell, Jordan D., Fan, Cheng, Selitsky, Sara, Fernandez-Martinez, Aranzazu, Parker, Joel S., Hoadley, Katherine A., Hu, Zhiyuan, Li, Yan, Soloway, Matthew G., Spears, Patricia A., Singh, Baljit, Tolaney, Sara M., Somlo, George, Port, Elisa R., Ma, Cynthia, Kuzma, Charles, Mamounas, Eleftherios, Golshan, Mehra, Bellon, Jennifer R., Collyar, Deborah, Hahn, Olwen M., Hudis, Clifford A., Winer, Eric P., Partridge, Ann, Hyslop, Terry, Carey, Lisa A., Perou, Charles M., Sikov, William M.
Publicado 2022